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Abstract
Intestinal myeloid cells play a critical role in balancing intestinal homeostasis and inflammation.
Here, we report that expression of the autophagy-related 5 [Atg5] protein in myeloid cells prevents
dysbiosis and excessive intestinal inflammation by limiting IL-12 production. Mice with a selective
genetic deletion of Atg5 in myeloid cells [Atg5ΔMye] showed signs of dysbiosis preceding colitis,
and exhibited severe intestinal inflammation upon colitis induction that was characterised by
increased IFNγ production. The exacerbated colitis was linked to excess IL-12 secretion from
Atg5-deficient myeloid cells and gut dysbiosis. Restoration of the intestinal microbiota or genetic
deletion of IL-12 in Atg5ΔMye mice attenuated the intestinal inflammation in Atg5ΔMye mice.
Additionally, Atg5 functions to limit IL-12 secretion through modulation of late endosome [LE]
acidity. Last, the autophagy cargo receptor NBR1, which accumulates in Atg5-deficient cells, played
a role by delivering IL-12 to LE. In summary, Atg5 expression in intestinal myeloid cells acts as an
anti-inflammatory brake to regulate IL-12, thus preventing dysbiosis and uncontrolled IFNγ-driven
intestinal inflammation.

© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved.
For permissions, please email: journals.permissions@oup.com
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Graphical abstract
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1. Introduction
Immune system dysregulation, intestinal barrier defects, and
dysbiosis are believed to be driven in part by genetics, according
to recent genome-wide association studies [GWAS].1 Many of the
identified genes are involved in innate cell bacterial recognition and
processing, and appear to contribute to the pathogenesis observed in
inflammatory bowel disease [IBD], such as NOD2 and ATG16L1
which are linked to autophagy.1 Autophagy is one such process associated with IBD susceptibility.2–11 Autophagy is a conserved catabolic process that degrades protein aggregates, damaged organelles,
and numerous pathogens.12 Autophagy has proven critical for intestinal homeostasis. Defects in the autophagic pathway, specifically in
intestinal epithelial cell lineages, results in increased intestinal permeability and Paneth and goblet cell [GC] dysfunction.13–18 More
recently, an IBD risk locus associated with autophagy was found
to disrupt the microbiota, albeit it is unclear what cell type mediates this effect.19 Nevertheless, there is mounting evidence that
autophagic genes are critical for intestinal homeostasis, and defects
in the autophagic process can lead to increased susceptibility to intestinal pathogens and overall enhanced IBD susceptibility.6,20–22
Many of these IBD risk genes and pathways, including autophagy,
are highly relevant to myeloid cell function in addition to that of
epithelial cells.23–26 However, the specific role for autophagy and
autophagy genes in myeloid cells in maintaining the balance between intestinal homeostasis and inflammation has yet to be fully
explored. The prevailing hypothesis linking autophagy to IBD is
through the IL-17 signalling pathway. IL-1, IL-17, and IL-23, all involved in IL-17-mediated inflammation, are upregulated in IBD.27–36
Our previous work, as well as that of others, has demonstrated that

autophagy regulates the production of the proinflammatory cytokines IL-1α, IL-1β, and IL-23, primarily in infection models.37–42
This observation is the canonical pathway frequently described
linking autophagy dysregulation to excess inflammation via IL-1
and IL-17. IL-1 and IL-23 are key regulators of IL-17-mediated
inflammation.43,44 However, the role of IL-17 in IBD pathogenesis
has recently been questioned, as therapeutic targeting of IL-17 exacerbates inflammation in both IBD patients and animal models of
IBD,45–49 suggesting that IL-17 may not be the predominant driver
of autophagy-linked IBD pathogenesis. Thus, there is a clear gap in
knowledge regarding which inflammatory pathway might underlie
IBD pathology with respect to autophagy dysregulation.
This study assessed the role of the autophagy gene Atg5 in myeloid cells in maintaining the balance between intestinal homeostasis
and inflammation. Atg5’s most well-understood actions are via the
Atg5-Atg12-Atg16L1 complex, which acts as the E3 enzyme conjugating PE to LC3, and along with the E1-like actions of Atg7 and
the E2-like actions of Atg3, this pathway drives isolation membrane formation and eventual autophagosome maturation.50–53 Atg5
is also embedded in autophagosomal membranes, which allows it
to interact with fusion proteins in lysosomal membranes such as
Tectonic β-propeller repeat containing 1 [TECRP] that facilitate
autophagosome-lysosome fusion.54,55 Thus, Atg5 plays a major role
in selective and bulk autophagy which are critical for cell autonomous immunity. However, it is unclear how Atg5 expression, specifically in myeloid cells, functions outside of bacterial recognition and
processing. Here, we show at steady state that mice with an Atg5deficiency in myeloid cells [herein called Atg5ΔMye mice]37,56 show
alterations in the gut microbiota as well as mucosal TH1 [IFNγ]

Atg5 Limits IL-12 mediated Inflammation

B

Microbiota composition
(% of total population)

Bacteroidetes

*

Atg5∆Mye

40

70
Firmicutes
Bacteroidetes
Actinobacteria
Proteobacteria
Other

60
50
40

*

50

Percentage

Atg5-Wt

C

Firmicutes

80

Percentage

A

261

30
20
10
0

Atg5-Wt Atg5∆Mye

D

Actinobacteria

Atg5-Wt Atg5∆Mye

E

Proteobacteria
2.5

15

F

–1

0

1

2

10

Percentage

Atg5∆Mye

Percentage

2.0

Atg5-Wt

5

1.5
1.0
0.5

0

PC2 (18%)

Sporacetigenium
Phaeospirillum
Pseudomonas
Listeria
Rhodanobacter G
Mangroviflexus
Anaerobranca
Marininema
Legionella
Helicobacter
Romboutsia
Intestinibacter
Tepidibacter
Zhongshania
Salinithrix
Faecalitalea
Sphingobacterium
Holdemanella
Acetitomaculum
Ruminococcus
Gp14
Youngiibacter
Anaerorhabdus
Olsenella

Atg5-Wt Atg5∆Mye

0.0

Atg5-Wt Atg5∆Mye

Microbiota composition
(16S profiling)
4

Atg5-Wt
Atg5∆Mye

2
0
–2
–4
–6
–8
–4

–2

2
0
PC1 (28%)

4

6

Figure 1. Alterations in the composition of the colonic microbial community in mice with a selective Atg5-deficiency in myeloid cells. Bacterial composition
as assessed by 16S rRNA sequencing of DNA extracted from freshly collected stool of Atg5-Wt and Atg5ΔMye mice [n = 5 per group]. [A] Pie chart showing
the average proportion of Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and all other phyla in 8-week old mice. [B‐E] Quantification of the phyla [B]
Firmicutes, [C] Bacteroidetes, [D] Actinobacteria, and [E] Proteobacteria. [F] Heatmap of the relative abundance of colonic microbes [genus level]. [G] Principal
coordinates analysis [PCoA] plot of microbiota composition [genus level]. Data are shown as mean (±95% confidence interval [CI]) and a t test was used to
measure specific microbiome species abundance between groups. Adjusted p-value >0.05 was used as significant threshold.

skewing. Atg5ΔMye mice were susceptible to chemically-induced
colitis that was characterised by an enhanced IFNγ response. Both
TH1 skewing and microbiota changes were partly driven through
IL-12 dysregulation in Atg5-deficient myeloid cells. Confirming our
findings, Atg5ΔMye mice crossed with IL12p35-deficient mice resulted in restoration of the gut microbiota and protection from dextran sodium sulphate [DSS]-induced colitis through the reduction of
the IL-12 pathway. In addition, faecal microbiota transplant of control microbiota into Atg5ΔMye mice reduced chemically-induced
colitis, suggesting the Atg5ΔMye-associated microbiota also contributes to the exacerbated colitis phenotype in Atg5ΔMye mice. We
further show IL-12 regulation was not mediated through autophagy
but through interactions with sequestosome-1-like receptor NBR1
and Atg5 action on late endosomes [LE]. There has not been a single
description of autophagic proteins regulating IL-12-driven immune

responses. Thus, these data indicate a new autophagy-independent
role for Atg5 and NBR1 in myeloid cells in influencing intestinal
homeostasis through an IL-12 pathway.

2. Results
2.1. Altered colonic microbiota in mice with an
Atg5-deficiency in myeloid cells
The gut microbiota is influenced by environmental factors, immune
responses, and genetics which is highlighted in individuals with
IBD. Numerous studies have reported a decrease in bacterial diversity in IBD patients, with major alterations in the phyla Firmicutes
and Bacteroidetes.57–62 There is substantial evidence that intestinal myeloid cells are regulated by commensal microbiota.58,63–66
However, numerous studies have emerged demonstrating myeloid

262

S. D. Merkley et al.

Figure 2. Myeloid Atg5 expression prevents excessive DSS-induced colitis and an accumulation of lamina propria myeloid cells. DSS-induced colitis and myeloid
cell response in Atg5-Wt and Atg5ΔMye mice. [A] Percent weight loss between Atg5-Wt and Atg5ΔMye mice. [B] Disease activity index [DAI] as determined by
weight loss, behaviour, acute diarrhoeal response, and mucosal bleeding. [C] H&E staining of colon sections. [D] Histological scores. [E] Representative gross
anatomy of the caecum and colon of colitic Atg5-Wt and Atg5ΔMye mice. [F] Colon length after colitis. [G] Spleen weight after colitis. [H] Dot plots showing
lamina propria [gated on CD45+CD11b+ cells] monocyte waterfall as determined by Ly6C and MHC II staining after colitis. [I] Graph showing percent of P1
[Ly6C+MHC IILow] cells. [J] Graph showing percent of P2 [Ly6C+MHC II+] cells. [K] Graph showing percent of P3-4 [Ly6CLowMHC II+] cells. [L] Dot plots showing F4/80
expression and CX3CR1 expression on P3-P4 gated cells in H. [M] Graph showing percent of P3 [Ly6CLowMHC II+CX3CR1Low] cells. [N] Graph showing percent
of P4 [Ly6CLowMHC II+CX3CR1+] cells. Representative of three independent experiments, Graphs indicate mean [±SD]; *p <0.05, **p <0.01. Two-tailed unpaired
Student’s t tests or by two-way ANOVA with Tukey’s post hoc test. DSS, dextran sodium sulphate; H&E, haematoxylin and eosin; SD, standard deviation; ANOVA,
analysis of variance.

regulation of the microbiota.67–70 Autophagy genes appear to be
involved in the latter as it was shown the autophagy protein,
Atg16L1, expressed in myeloid cells from both humans and mice,
altered IgA-coated intestinal bacteria at steady state and during
inflammation,26 but it was not confirmed if this increase in IgAcoated bacteria affects the overall microbial community. More recently, another mouse model with a global knockin of the IBD risk
allele ATG16L1 T300A had an altered gut microbiota preceding
colitis induction.19

Using Atg5ΔMye mice [myeloid specific loss of autophagyrelated 5, Atg5, gene], we investigated the importance of Atg5 expression in myeloid cells in maintaining the intestinal microbiota.37,56
In comparison with littermate controls [Atg5-Wild-type, Atg5-Wt],
Atg5ΔMye mice showed significant differences in the intestinal microbial composition [Figure 1A]. Similar to what is observed in
IBD patients,59–62,71 Atg5ΔMye mice had a decrease in the phylum
Firmicutes [Figure 1B] and an increase in the phylum Bacteroidetes
[Figure 1C] compared with Atg5-Wt mice. No significant changes
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2.2. Myeloid Atg5 expression regulates IFNγ
response in the intestinal microenvironment
The acute DSS-induced colitis model is an innate/wound repair
model that is sensitive to the gut microbiota.72,73 To examine the
impact of the microbiota alteration in Atg5ΔMye mice during an
inflammatory state, we subjected both Atg5ΔMye and Atg5-Wt
mice to DSS-induced acute colitis. Similar to what was reported
in mice with an Atg16l1- or Atg7-deficiency specifically in myeloid cells,26,74 colitis induction in Atg5ΔMye mice resulted in an
exacerbated inflammatory response compared with Atg5-Wt mice.

A

Intestinal epithelial disruption via DSS caused significant weight
loss [Figure 2A] as well as acute diarrhoeal response and mucosal
bleeding [disease activity index, DAI, Figure 2B] in Atg5ΔMye mice;
however, histologically both groups showed inflammation [Figure
2C and D]. Severe inflammation from the caecum to the distal
colon of Atg5ΔMye mice was observed [Figure 2E]. The length of
the colon was also measured to assess colonic mucosal injury and
revealed colonic shortening [Figure 2F]. We also found that the
spleen weight of colitic Atg5ΔMye mice was increased [Figure 2G].
Examination of the cellular infiltration in the colonic lamina propria [LP] during DSS-induced colitis revealed a significant increase in
polymorphonuclear [PMN] leukocytes [Ly6GhighCD11b+] in colitic
Atg5ΔMye mice compared with colitic controls [Supplementary
Figure 2A and B, available as Supplementary data at ECCO-JCC
online]. We also found an increase in monocytes and macrophages
that were distinguished by Ly6C, MHCII, and CX3CR1 expression
[Figure 2H–N]. Colonic macrophages are replenished by monocytes through a differentiation process called the monocyte waterfall.75–78 Ly6ChighMHCII− [P1] monocytes acquire MHCII to become
Ly6ChighMHCII+ monocytes [P2]. These monocytes then differentiate
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Figure 3. Myeloid Atg5 expression prevents excessive IFNγ-mediated intestinal inflammation. Analysis of colonic IFNγ production after colitis induction. [A]
Dot plots showing LP CD4+ T cells staining after colitis. [B] Intracellular IFNγ staining in LP CD4+ T cells. [C] Intracellular IL-17A staining in LP CD4+ T cells. [D]
Graph showing the percent of IFNγ +CD4+ T cells isolated from the LP of colitic mice. [E] Graph showing the percent of IL-17A+CD4+ T cells isolated from the LP
of colitic mice. [F] Colonic Ifng and [G] Il17a gene expression after colitis induction. [H] Colonic IFNγ and [I] IL-17 protein expression as determined by ELISA.
Representative of three independent experiments. Graphs indicate mean [±SD]; *p <0.05, **p <0.01, Two-tailed unpaired Student’s t tests. LP, lamina propria;
ELISA, enzyme-linked immunosorbent assay.
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into macrophages Ly6C-MHCII+ [P3-4] after downregulating
Ly6C and then become fully mature macrophages by upregulating
CX3CR1 [P4]. We find P1 [Figure 2I], P2 [Figure 2J], and the P3-4
mixed [Figure 2K] subsets are significantly increased in the LP of
colitic Atg5ΔMye mice compared with colitic control mice; however, P3 and P4 subsets were not significantly different [Figure
2L–N]. During colitis, pro-inflammatory Ly6C+MHCII+ monocytes [P2] accumulate in the colon,79 which we find are increased
in Atg5ΔMye mice [Figure 2J]. P4 macrophages from Atg5ΔMye
mice also showed a general increase in TLR4 [Supplementary Figure
2C and G], CD14 [Supplementary Figure 2E and I], and CD115
[Supplementary Figure 2F and J] expression while expressing lower
levels of CD206 [Supplementary Figure 2D and H] compared with
P4 macrophages isolated from colitic control mice; however, only
the levels of CD115 were significantly increased in the LP of colitic
Atg5ΔMye mice. Overall, these results indicate that Atg5 expression
in myeloid cells, like Atg7 and Atg16L1, is critical to control acute
intestinal inflammation.
The proinflammatory cytokine IL-17 contributes to shaping
and regulating the intestinal microbiota. We and others have
shown that T cells from mice wherein myeloid cells lack Atg5 or
other autophagy-related genes display skewing towards IL-17 polarisation.37,39–41 This T cell polarisation is mediated through the
dysregulation of cytokines or cellular components that promote
IL-17 responses.43,44 Microbiota differences can also alter T cell polarisation.80–84 Although the acute DSS model is not solely dependent
on B and T cell responses, both participate in the exaggerated presentation of the disease. In fact, T cells have been shown to be the
major driver of colonic inflammation in the acute DSS model by
Day 4, with a peak at Day 8.85 Interestingly, we do not see major
changes in DAI in Atg5ΔMye mice until Days 6 and 7 [Figure 2B]
when we would expect T cells to be responding. To determine
whether an enhanced level of IL-17-producing T cells populating
the intestinal mucosa is influencing the microbiota of Atg5ΔMye
mice and contributing to this excess inflammatory response, we isolated and stimulated CD4+ T cells from the colon lamina propria
[LP] of mice during DSS treatment to determine TH polarisation.
Interestingly, we observed an increase in IFNγ-producing CD4+ T
cells isolated from the colonic LP of Atg5ΔMye mice [Figure 3A,
B, and D]. Colitic colons from Atg5ΔMye mice also showed an increased IFNγ gene and protein expression compared with controls
[Figure 3F and H]. Additionally, there was also an increase in IFNγproducing CD4+ T cells isolated from the mesenteric lymph nodes
(mLN) of colitic Atg5ΔMye mice [Supplementary Figure 3A, available as Supplementary data at ECCO-JCC online]. We also observed
a significant reduction in IL-17-producing CD4+ T cells isolated from
the colon of Atg5ΔMye mice compared with controls [Figure 3A, C,
and E]. An although there was a difference in IL-17-producing CD4+
T cells in the colon, we found no significant difference in IL-17 gene
and protein expression in the colon from both colitic Atg5ΔMye
and Atg5-Wt mice [Figure 3G and I] or from mLN CD4+ T cells
[Supplementary Figure 3B].
Our observation that CD4+ T cells are skewed towards a type
1 immune response in Atg5ΔMye mice after colitis induction
prompted an examination of cytokine expression and TH skewing at
steady state. Spontaneous colitis never occurred in Atg5ΔMye mice
but, similar to what was observed during colitis, we observed an
increase in IFNγ-producing CD4+ T cells isolated from the colonic
LP of Atg5ΔMye mice [Supplementary Figure 3C and D] with no
significant difference in the number of IL-17-producing CD4+ T cells
[Supplementary Figure 3E and F] at steady state. This discrepancy in
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IL-17 expression could be tissue-specific, as models in which myeloid
cells lack autophagic components and express high levels of IL-17
have been reported for only respiratory infections.37,40,41 However,
others have reported TH1 skewing in ATG16L1T300A knockin
mice as well as in conditional myeloid Atg7-deficient mice during
intestinal inflammation.19,26 Furthermore, IFNγ has been shown to
play an indispensable role in the initiation of acute DSS colitis, and
IFNγ-deficient mice are protected from acute DSS-induced colitis.86
Thus, this model is sufficient to show IFNγ responses from T cells in
Atg5ΔMye mice. Overall, at steady state and during inflammation,
Atg5ΔMye mice show differences in CD4+ T cell polarisation in the
colon particularly to a type 1 immune response.

2.3. Atg5 limits IL-12 production in myeloid cells
independent of canonical autophagy
The current paradigm is that an autophagic defect [or loss of an
autophagy-related gene] in myeloid cells leads to enhanced IL-1α/β
expression.37–39 The excess production of IL-1 skews lymphocytes
to produce IL-17, subsequently promoting IL-17-mediated inflammation. However, we found colitic Atg5ΔMye mice presented with
increased IFNγ and no significant difference in IL-17 in the colon
microenvironment. This suggests that colonic Atg5-deficient myeloid
cells are likely to produce other factors that promote TH1 skewing
and IFNγ production. IL-12p70 [hereafter called IL-12] is a major
cytokine involved in TH1 polarisation and is a potent inducer of
IFNγ.35,87–89 IL-12 is a heterodimeric protein comprising IL-12p35
and IL-12p40 [IL-12p40 also dimerises with IL-23p19 to form IL-23,
a major cytokine maintaining TH17 cells] and is highly expressed by
various myeloid cells including macrophages.35,90–93 We have previously shown that Atg5ΔMye mice also produce excess IL-12 during
tuberculosis infection.37 Examination of the colon at steady state and
during colitis revealed a general increase in IL-12 gene and protein
expression [Supplementary Figure 3G–L] in Atg5ΔMye mice. This
increase in colonic IL-12 suggests the cytokines required to promote
type 1 immune responses are present in the colonic microenvironment of Atg5ΔMye mice. Nevertheless, it is unclear if this excess
IL-12 is coming from Atg5-deficient myeloid cells.
We next set out to determine if Atg5-deficient myeloid cells
produce excess IL-12. Using bone marrow-derived macrophages
[BMM] from Atg5ΔMye and Atg5-Wt mice, we showed that Atg5deficient macrophages secrete excess IL-12 upon LPS/IFN-γ stimulation compared with Atg5-Wt macrophages [Figure 4A]. For many
cell types, low levels of IL-12p35 are constitutively expressed,
whereas IL-12p40 expression occurs primarily in macrophages and
dendritic cells, and both increase in response to microbial stimulation.90–93 We observed no difference in Il12a [IL-12p35] and Il12b
[IL-12p40] gene expression [Supplementary Figure 4A and B, available as Supplementary data at ECCO-JCC online]. Furthermore,
there was no difference in cell surface expression of IFNγ-receptor,
TLR4/MD2, or CD14 between Atg5-Wt and Atg5-deficient BMM
[Supplementary Figure 4C] that would enable an enhanced response.
These data suggest that Atg5 has a post-transcriptional role in regulating IL-12 secretion.
As mentioned above, Atg5 assists in autophagosome formation
and autophagosome-lysosome fusion. Thus, the genetic deletion of
Atg5 would consequently affect several steps in autophagy. We next
considered whether IL-12 was a direct target for autophagic removal.
However, endogenous IL-12 and LC3 did not co-localise during stimulation and treatment with bafilomycin A1 [Baf. A1] [Supplementary
Figure 4D] in Atg5-Wt or Atg5-deficient BMM, suggesting that IL-12
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Figure 4. Atg5 regulates IL-12 secretion in macrophages. Analysis of IL-12 secretion in macrophages. [A] Detection of IL-12 by ELISA from Atg5-Wt or Atg5ΔMye
BMM after LPS and IFNγ stimulation. [B and C] Detection of IL-12 by ELISA from Atg5-Wt [B] or Atg5ΔMye [C] BMM after LPS and IFNγ stimulation in the
presence or absence of Baf. A1. Representative of two independent of experiments. [D‐F] 1–3 µm Z-stack images were performed on BMM stimulated with LPS,
IFNγ, and Baf. A1 using immunofluorescence at 1.6 Zoom by a 63x oil immersion objective. [D] Atg5-Wt BMM were stained for LAMP1 [green] and IL-12p35
[red]. [E] Atg5-Wt BMM were stained for ATG5 [red] and IL-12p35 [green]. [F] Atg5ΔMye BMM were stained for LAMP1 [green] and IL-12p35 [red]. Representative
from 65 images from 15 slides from two independent of experiments. Arrows in images indicate puncta co-localising with insets displaying enlargement of
indicated region. Scale bars: 10 µm. Graphs indicate mean [±SD]; *p <0.05, **p <0.01,***p <0.001. Two-tailed unpaired Student’s t tests. ELISA, enzyme-linked
immunosorbent assay; BMM, bone marrow-derived macrophages; LPS, lipopolysaccharide; SD,standard deviation.

is unlikely to be a direct target for autophagic degradation. Baf. A1
is widely used to inhibit autophagic flux by targeting the V-ATPase
ATP6V0C/V0 subunit c, but can also de-acidify endosome/lysosome
vesicles through the same mechanism.94,95 Atg5 also regulates acidification and de-acidification of late endosomal compartments96 and,
before stimulation, Atg5-deficient BMM display increased lysotracker
staining compared with Atg5-Wt BMM [Supplementary Figure 4E],

suggesting that the loss of Atg5 affects the regulation of vesicles’ pH
levels.96,97 Interestingly, Baf. A1 treatment decreased IL-12 secretion
in Atg5-Wt BMM [Figure 4B]. Furthermore, treatment of Atg5deficient BMM with Baf. A1 also reduced IL-12 secretion [Figure
4C]. These data suggest that Atg5 regulates IL-12 secretion through
vesicle acidification, and Baf. A1 can compensate for the loss of Atg5
in regulating IL-12 secretion.
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Figure 5. NBR1 and IL-12 interaction. Analysis of NBR1 and IL-12 interaction in macrophages. [A] Atg5-Wt BMM were stained for NBR1 [red] and IL-12p35 [green]
after LPS and IFNγ stimulation and the addition of Bafilomycin A1 [top row] or Brefeldin A [bottom row]. [B] Quantification was performed using Pearson’s
correlation coefficient [co-localisation] using image analysis. Representative of two independent of experiments and of 10 images from five slides. Arrows in
images indicate puncta co-localising with insets displaying enlargement of indicated region. Scale bars: 10 µm. [C] Anti-IL-12p35 antibody co-immunoprecipitated
NBR1 and IL-12p40, and anti-NBR1 antibody co-immunoprecipitated IL-12p35 and IL-12p40. [D and E] Protein docking between IL12A [PDB ID: 1F45] and NBR1.
[D] The docking models and [E] ClusPro docking results for four candidate interaction models between 1F45 and four peptide fragments of NBR1 [PDB IDs:
1WJ6, 2L8J, 2MGW, and 2MJ5]. [F and G] Effects of NBR1 knockdown on IL-12 secretion in Atg5-Wt or Atg5ΔMye BMM. Graphs indicate mean [±SD]. * p < 0.05,
**p < 0.01. Two-tailed unpaired Student’s t tests. BMM, bone marrow-derived macrophages; LPS, lipopolysaccharide; SD,standard deviation.

We next examined the intracellular localisation of IL-12 after
Baf. A1 treatment. As mentioned above, IL-12 consists of subunits
IL-12p35 and IL-12p40. Whereas the IL-12p40 subunit has conventional secretory sequences and can be secreted in its homodimeric

form, the IL-12p35 peptide is leaderless, cannot be secreted as a
monomer, and conventional secretion cannot be induced by the addition of a secretory sequence.90,91,93 The purpose of IL-12p35’s constitutive expression remains poorly understood,90 but a recent report
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demonstrated that IL-12p35 is trafficked to late endosomes [LE] before secretion.98 As observed with total IL-12, Baf. A1 treatment resulted in IL-12p35 accumulation in LE as determined by IL-12p35
[red] and Lamp1 [green] co-localisation [Figure 4D]. White arrows
in images indicate puncta co-localising with insets displaying enlargement of indicated region. Interestingly, IL-12p35 [green] co-localised
with Atg5 [red] [Figure 4E]. IL-12 [red] co-localisation with Lamp1
[green] was more evident in Atg5-deficient BMM [Figure 4F]. Further
analysis revealed that IL-12 [red] also co-localised with the LE marker
Rab7 [green] [Supplementary Figure 4F], as previously reported.98
Taken together, our data suggest that Lamp1+ LEs99,100 contain IL-12,
and the lack of Atg5 leads to increased levels of IL-12 in these vesicles.

2.4. The sequestosome-1-like receptor NBR1 is
involved in IL-12 secretion
Most cytokines are directed by their signal sequence through endoplasmic reticulum [ER]-golgi complex pathway for processing and
trafficking, but some inflammatory cytokines, including IL-1β and
IL-18, are known to be excreted via alternative strategies.38,101–105
For IL-1β, the selective autophagy cargo receptor TRIM16 directs
IL-1β to LC3-II+ sequestration membranes for secretion.103 This suggests that other selective cargo receptors, such as the sequestosome1-like receptors [SLRs: p62/SQSTM1 and NBR1], could act as
possible cargo receptors for alternative secretion.102,105,106 We considered that NBR1 might be responsible for delivering IL-12 to LE
for secretion given a homologue of the mammalian NBR1; Nbr1
from Schizosaccharomyces pombe was shown to deliver proteins to
LE,107 and NBR1 accumulates upon autophagy inhibition.108 Indeed,
confocal imaging revealed NBR1 [red] co-localised with IL-12p35
[green] in WT BMM after LPS/IFN-γ and Baf. A1 treatment [Figure
5A, top row, and B]; white arrows indicate puncta co-localising.
However, this co-localisation was reduced upon brefeldin A [BrefA]
treatment, suggesting that NBR1 [red] and IL-12 [green] interaction
occurs after IL-12 leaves the ER [Figure 5A, bottom row, and B].
This reduction in co-localisation was not due to enhanced secretion, as IL-12 was undetectable by enzyme-linked immunosorbent
assay [ELISA] after LPS/IFNγ/brefA treatment [data not shown].
To verify NBR1/IL-12 interaction in macrophages, cell lysates were
immunoprecipitated with anti-IL12p35, anti-NBR1, or isotype control antibodies, and subjected to western blot with anti-IL-12p35,
anti-IL-12p40, anti-NBR1, and anti-p62 antibodies. Both IL-12p40
and NBR1 co-precipitated with anti-IL-12p35 antibodies [Figure
5C]. Reciprocally, IL-12p35 and IL-12p40 co-precipitated with antiNBR1 antibodies [Figure 5C]; however, neither probe co-precipitated
p62/SQSTM1 [Figure 5C]. This interaction was further verified in
silico through ClusPro docking,109 as IL-12 [1F45] interacted with
multiple peptide fragments [1WJ6, 2L8J, 2MGW, and 2MJ5] of
NBR1 [Figure 5D and E]. Lastly, a knockdown of NBR1 via small
interfering RNA [siRNA] in Atg5-Wt BMM reduced IL-12 secretion
compared with scrambled siRNA control [Figure 5F; Supplementary
Figure 4G]. A reduction in IL-12 secretion was also observed in Atg5deficient BMM after NBR1 knockdown, suggesting this interaction is
independent of Atg5 [Figure 5G; Supplementary Figure 4G]. Taken
together, our data suggest NBR1 is partially responsible for IL-12
secretion whereby it functions to direct IL-12p35 to LE for secretion.

2.5. IL-12 and the Atg5ΔMye gut microbiota
contribute to the exacerbated intestinal
inflammation
We found the exacerbated intestinal inflammation in Atg5ΔMye
mice coincides with dysregulated IL-12 levels. Although this is the
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first finding linking Atg5 to IL-12 secretion, IL-12 has been associated with intestinal inflammation87,110 and it has been targeted
therapeutically to attenuate intestinal inflammation. In both chemically induced colitis and genetic-deficient mouse models of colitis,
antibodies against IL-12 prevented intestinal inflammation.110–114
Clinical trials have also been performed in individuals with IBD,
using antibodies against the IL-12p40 subunit.48,115–119 These antibodies target both IL-12 and IL-23 pathways and has proven to
be a safe and effective treatment approach in patients with IBD.
Antibodies against IL-12/IL-23 also show efficacy in patients who
failed treatment with anti–TNF-α agents, and the efficacy is more
pronounced among secondary non-responders. Nevertheless, it unclear if IL-12 is leading to the changes in the gut microbiota and
susceptibility to DSS-induced colitis we observe in Atg5ΔMye mice.
Given the antibodies target both IL-12 and IL-23, we decided to
target only IL-12 by crossing Atg5ΔMye mice with IL-12p35deficient mice120 to generate Atg5ΔMye-IL12KO mice. We first
examined the colonic microbiota at steady state in all three groups
of mice [i.e., Atg5-Wt, Atg5ΔMye and Atg5ΔMye-IL12KO].
Atg5ΔMye-IL12KO mice showed a global change in the intestinal microbial composition in comparison with Atg5ΔMye mice,
particularly an increase in the phylum Firmicutes [Supplementary
Figure 5A, available as Supplementary data at ECCO-JCC online].
Furthermore, the PCoA plots and heatmap show clustering of the
bacterial communities [at genus level] of the Atg5ΔMye-IL12KO
and Atg5-Wt colonic mice which was separated from the bacterial
community in the Atg5ΔMye mice [Figure 6A and B].
We next examined Atg5ΔMye-L12KO mice response to DSSinduced colitis. Atg5ΔMye-IL12KO mice were protected from DSSinduced colitis compared with Atg5ΔMye mice. Atg5ΔMye-IL12KO
mice suffered minimal weight loss, showed no shortening of the
colon after colitis induction, and had reduced spleen weights [Figure
6C–E]; however, no major changes were observed by histology
[Supplementary Figure 5B and C]. There was also a decrease in Ifng
gene expression in the colon after colitis induction in Atg5ΔMyeIL12KO mice, but no change in Il17a gene expression between both
groups of mice [Figure 3F and G]. Isolation and stimulation of colonic LP CD4+ T cells showed a decrease in IFNγ-producing CD4+ T
cells from Atg5ΔMye-IL12KO mice compared with Atg5ΔMye mice
[Figure 6H and I]. Additionally, we observed a decrease in the percent of IFNγ-producing CD4+ T cells from the mLN of Atg5ΔMyeIL12KO mice compared with Atg5ΔMye mice [Supplementary
Figure 5D]. However, Atg5ΔMye-IL12KO mLN CD4+ T cells did
produce more IL-17 [Supplementary Figure 5E]. This change in
IL-17 expression is likely due to Atg5-deficient myeloid cells producing excess IL-1.37 Nevertheless, genetic deletion of IL-12p35 from
mice in which myeloid cells also lack Atg5 restores the microbiota
and protects against DSS-induced colitis.
The DSS-induced colitis model is sensitive to the gut microbiota.72,73 The restoration of the microbiota in Atg5ΔMye-IL12KO
mice [Figure 6A and B] which coincides with attenuated intestinal
inflammation suggest that the Atg5ΔMye-associated gut microbiota may play a role in the exacerbated inflammation observed
in Atg5ΔMye mice. Therefore, we performed a faecal microbiota
transplant [FMT] in Atg5ΔMye mice to examine the pathogenic
potential of the Atg5ΔMye-associated gut microbiota. First, the
microbiota was ablated in a several groups of Atg5ΔMye mice via
antibiotic treatment and microbiota was collected from fresh stool
samples from either Atg5ΔMye or Atg5-Wt mice. Antibiotic-treated
Atg5ΔMye mice were then orally gavaged with Atg5-Wt-associated
microbiota, Atg5ΔMye-associated microbiota, or carrier solution.
One week after FMT, mice were subjected to DSS-supplemented
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Figure 6. Limiting IL-12 in mice with a selective Atg5-deficiency in myeloid cells restores the intestinal microbiota and alleviates inflammation. Bacterial
composition as assessed by 16S rRNA sequencing from freshly collected stool of Atg5ΔMye and Atg5ΔMye-IL12KO mice before colitis induction [n = 5 per
group]. [A] Principal coordinates analysis [PCoA] plot of microbiota composition [genus level]. [B] Heatmap of the relative abundance of colonic microbes
[genus level]. A t test was used to measure specific microbiome species abundance between groups. Adjusted p-value >0.05 was used as significant threshold.
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water for 7 days. Daily assessment revealed significant weight loss
in Atg5ΔMye mice receiving Atg5ΔMye microbiota compared with
microbiota-free Atg5ΔMye mice [Figure 6J]. This was also observed
in Atg5ΔMye mice receiving Atg5-Wt microbiota when compared
with microbiota-free Atg5ΔMye mice [Figure 6J]. Interestingly,
microbiota-free Atg5ΔMye mice subjected to DSS had minimal
weight loss. Furthermore, the DAI revealed a significant difference
between Atg5ΔMye mice receiving FMT of Atg5ΔMye microbiota
compared with microbiota-free Atg5ΔMye mice at Day 7 [Figure 6J;
Supplementary Figure 5F]. Assessment of the stool for lipocalin-2
[Lcn-2], a marker of intestinal inflammation,121–123 at Day 7 revealed FMT of Atg5ΔMye microbiota had significantly increased
faecal Lcn-2 levels compared with Atg5ΔMye mice with no FMT
as well as mice receiving a FMT of Atg5-Wt microbiota [Figure 6K].
Additionally, proximal colons were immediately removed, cleaned,
and then incubated for 4 h in RPMI.124 After the incubation period,
the colon and supernatant [concentrated through centrifugation]
were prepared for IL-12p35 immunoblot [Supplementary Figure
5G–I]. No significant change was observed for the colon between
FMT-treated mice, but the concentrated supernatant from the colon
of Atg5ΔMye mice receiving FMT of Atg5ΔMye microbiota showed
an increase in IL-12 [Supplementary Figure 5G and I]. Overall, this
suggest that the gut microbiota of Atg5ΔMye mice also contributes
to the increased IL-12 and exacerbated colitis we have observed
[Figure 2].

3. Discussion
This work identifies a role for Atg5 in myeloid cells in unconventional cytokine secretion that consequently affects intestinal homeostasis. Additionally, it adds to the plethora of functions described
for Atg5.96,97,125–129 Along with these studies, this work establishes a
new non-autophagy, immunological role for Atg5 in promoting TH1
responses. In the context of IBD and autophagy-related proteins
[Atg], GWAS have only identified ATG16L1 variants.3 Nevertheless,
animal models with an Atg5-deficiency display a similar phenotype
to Atg16L1-deficient mice.14 Interestingly, the levels of ATG5 and
the function of autophagy [and possibly other ATG5 functions] are
decreased in IBD patient samples. This decrease in ATG5 expression
and autophagy activity in IBD patients is linked to an increased expression of the microRNA miR30C that acts to downregulate ATG5
expression.55,130 Therefore, inhibiting Atg5 expression and function,
described here in only myeloid cells, ultimately alters the intestinal
microenvironment.
As previously reported, Atg5-deficient myeloid cells produce
excess pro-inflammatory cytokines including IL-1α and IL-1β.37,38
Thus, we cannot dismiss that either cytokine contributes to the excess
IFNγ observed in Atg5cKO mice, as IL-1 can synergise with IL-12
to enhance IFNγ production and TH1 skewing.131,132 Although we
and others did not find any changes in colonic IL-17-producing cells
in mice with a genetic deletion of Atg5 or Atg7 in myeloid cells,37,74
both colonic TH17 and TH1 cells were found to be increased in
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ATG16L1 T300A knockin mice.19 Given that Atg5ΔMye-IL12KO
mice were protected against colitis induction, these results together
suggest that IL-12 is a key cytokine driving intestinal pathology and
TH1 skewing in our model.
This similarilty in intestinal TH1 responses between these
mouse models is likely linked to the functional role of Atg5, Atg7,
and Atg16L1. All three proteins are involved in some aspect of
the autophagy process as well as endosome and lysosome regulation.12,107,133 The role of the TH17 response in driving intestinal pathology is up for debate as there is strong evidence suggesting that
IL-17 may have a protective role in the intestine. Exacerbated intestinal inflammation was reported in Il17a-deficient mice or after in
vivo blockade of IL-17 during DSS-induced colitis.47,49 Furthermore,
in clinical trials for IBD patients, targeting IL-17 or IL-17R worsened symptoms, leading to early clinical trial termination.46,134
Nevertheless, this does not rule out the effects of increased levels of
IL-17 during intestinal inflammation.30,35,45
Alterations in the gut microbiota have also been observed in
ATG16L1 T300A knockin mice. Similar to our findings, ATG16L1
T300A knockin mice also had a decrease in the phylum Firmicutes
and an increase in the phylum Bacteroidetes.19 It is unclear if these
microbiota changes in ATG16L1 T300A knockin mice are due specifically to myeloid cells, since all cells including the intestinal epithelium express the ATG16L1 T300A gene in this mouse model.
Furthermore, it is unclear if a certain genus that is lost/decreased
[Firmicutes] or gained/increased [Bacteroidetes] is the driver of intestinal inflammation in Atg5Mye mice. A caveat of our FMT study
is the potential loss of strictly anaerobic microorganisms after stool
collection and processing. Nevertheless, the identification of the
microorganism[s] driving intestinal inflammation could prove beneficial in individuals who have IBD associated with an autophagy risk
loci134; however, this is out of the scope of this study. Additionally,
IL-17 also plays a major role in regulating mucosal IgA production.136,137 Interestingly, increased IgA-coated bacteria were found in
mice that lack Atg16L1 in myeloid cells, as well as in the stool of
Crohn’s disease patients who were homozygous for the ATG16L1
T300A risk allele.26 Additionally, deletions or polymorphisms of
autophagy genes in myeloid cells alter bacterial clearance, suggesting
that there are multiple mechanisms by which autophagy genes regulate host-microbiota interactions. Our data suggest that myeloid
cells likely have a strong contribution in maintaining the microbiota
through Atg5’s action on IL-12 secretion.
The autophagic process and the genes that regulate autophagy
are crucial for intestinal homeostasis. Autophagy is required
for the maintenance of tight junction integrity, gut-commensal
homeostasis, and control of invasive bacteria at the intestinal epithelium.13–18,20–22,74,138 Multiple lines of evidence also suggest that
autophagy regulates inflammatory cytokines.37,38,139–141 These attributes make modulation of autophagy or single autophagic proteins an excellent therapeutic target. Nevertheless, it is critical to
understand the function of these individual proteins, given they can
modulate different TH responses. In fact, reagents that are known

[C] Percent weight loss between Atg5ΔMye and Atg5ΔMye-IL12KO mice. [D] Colon length after colitis. [E] Spleen weight after colitis. [F] Colonic Ifng and [G]
Il17a gene expression after colitis induction. [H] Intracellular IFNγ staining in LP CD4+ T cells after colitis induction. [I] Graph showing the percent of IFNγ +CD4+
T cells isolated from the LP of colitic mice. [J] Percent weight loss between Atg5ΔMye mice receiving [●] no microbiota, FMT of [■] Atg5-Wt microbiota, or [▲]
Atg5ΔMye microbiota [ƗAtg5-WT FMT vs no FMT, *Atg5ΔMye FMT vs no FMT]. [K] Disease activity index [DAI] as determined by weight loss, behaviour, acute
diarrhoeal response and mucosal bleeding at Day 7. [L] Faecal Lcn-2 levels as detected by ELISA from FMT Atg5ΔMye groups. Representative of two‐three
independent experiments. Graphs indicate mean [±SD]. * or Ɨp <0.05, ** or ƗƗp <0.01. Two-tailed unpaired Student’s t tests or by one- or two-way ANOVA with
Tukey’s post hoc test. LPS, lipopolysaccharide; SD,standard deviation; LP, lamina propria; ELISA, enzyme-linked immunosorbent assay; FMT, faecal microbiota
transplant; ANOVA, analysis of variance.
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to target autophagy activation, such as rapamycin, increase IL-12
secretion.142,143 Additionally chloroquine, a known inhibitor of
autophagosome-lysosome fusion, reduces IL-12 secretion144 likely
through a similar mechanism as does Baf. A1. These reagents have
been used with some clinical efficacy in IBD patients and animal
models of IBD.145–148 It is unclear if these effects were due to IL-12
regulation, but targeting IL-12, specifically the IL-12p40 subunit
that is shared with IL-23, has also proven beneficial for some IBD
patients.35,48,149 Therefore, understanding how autophagy or single
autophagic proteins regulate pro-inflammatory cytokines will allow
precision in modulating the immune system in chronic inflammatory conditions like IBD. Last, targeting these autophagy proteins
or their functions could be an alternative in mitigating problems associated with biologics, including loss of function, immunogenicity,
and cost.150
In conclusion, our data support a novel role for Atg5 expression
in myeloid cells in regulating intestinal homeostasis. Atg5 expression
in myeloid cells controls the IL-12-IFNγ pathway that influences the
microbiota and limits this pathway during colitis [Supplementary
Figure 5J]. Mechanistically, we show that both Atg5 and the cargo
receptor NBR1 regulate IL-12 secretion in myeloid cells. Specifically,
we propose that NBR1 shuttles IL-12 to LE, whereby Atg5 functions
to control the pH of these IL-12-containing vesicles for secretion.
A genetic deletion of Atg5 results in dysregulation of IL-12 secretion as well as the accumulation of SLRs such as NBR1,108 which
could potentially allow for increased accumulation of IL-12 in LE.
Consequently, these attributes increase IL-12 secretion. A reduction
in IL-12 secretion could be achieved by removing NBR1 or reducing LE/lysosomal pH with Baf. A1,- even in the absence of Atg5
expression. Nevertheless, the dysregulation of IL-12 in Atg5ΔMye
mice leads to alterations of the microbiota and severe colitis when
the intestinal barrier is disrupted.

4. Materials and Methods

rRNA as previously reported,151 with minor modifications described below. Microbial DNA was isolated from faeces using the
ZymoBIOMICS DNA Miniprep Kit [Zymo Research] following
manufacturer’s recommendations. Variable regions V-3 through V-4
of the 16S rRNA gene were amplified by polymerase chain reaction [PCR] using 100 ng input of DNA for each sample in duplicate, using primers 319F- [5’-ACTCCTRCGGGAGGCAGCAG-3’]
and 806R- [5’-GACAGGACTACHVGGGTATCTAATCC-3’] containing Nextera adapter overhangs. A second PCR was performed
with Nextera® XT Index Kit v2 Set A [Illumina] to complete the
adapter and add unique sample-specific barcodes. After each PCR,
a clean-up with AxyPrep Fragment Select-I magnetic beads [Axygen
Biosciences] was completed, and all PCR reactions were run on an
Applied Biosystems 2720 Thermal Cycler. Indexed samples were
combined to yield duplicate 300 ng pools, followed by the creation
and denaturation of a 4-nM library, and paired 250-bp sequencing
runs were completed on the Illumina MiSeq using v3 sequencing
chemistry [Illumina]. All reagents and kits are listed in Table S2,
available as Supplementary data at ECCO-JCC online.

4.4. Microscopy and image analysis
For confocal microscopy, macrophages were plated at 100 k cells per
well on 18-mm glass coverslips and stimulated with LPS [500 ng/
mL] and IFNɣ [10 ng/mL] for 8 h and treated with BrefA [10 nM]
or Baf. A1 [10 nM] for 2 h. Cells were then fixed with 4% PFA
followed by a wash with 1x PBS. Blocking buffer contained PBS
with 50% FBS, 2% BSA, and 0.1% saponin. After a 1-h stain in
primary antibody, cells were washed with PBS then followed by
1-h stain in blocking buffer containing secondary antibody. Cells
were mounted using ProLong Gold Antifade with DAPI and imaged
using the Zeiss LSM 800 Airyscan Confocal microscope with a 63x
oil objective lens. Images were processed using Zen Software and
Adobe Photoshop [version CC 2019]. All primary and secondary
antibodies used for confocal staining are listed in Table S3, available
as Supplementary data at ECCO-JCC online.

4.1. Animals
The transgenic Atg5ΔMye mice [myeloid specific Atg5 deletion]
and Atg5-Wt mice have previously been characterised.56 B6.129S1Il12atm1jm/J [IL-12p35-deficient mice] were purchased from JAX
[002692]119 and crossed to Atg5ΔMye mice to generate Atg5ΔMyeIL12KO mice. All mice were genotyped for the presence of Atg5,
Il12a or Cre expression by Transnetyx Inc. All experiments were
approved by the Institutional Animal Care and Use Committee of
the University of New Mexico Health Sciences Center, in accordance with the National Institutes of Health guidelines for use of
live animals. The University of New Mexico Health Sciences Center
is accredited by the American Association for Accreditation of
Laboratory Animal Care.

4.2. Intestinal inflammation model
For dextran sodium sulphate [DSS]-induced colitis, mice were
provided 2.5% DSS [colitis grade, ~30 000–50 000 MW; MP
Biomedicals] in drinking water ad libitum. Reagents used for in vivo
treatment as well as sample collection and stimulation are included
in Table S1, available as Supplementary data at ECCO-JCC online.

4.3. Microbiota analysis
Fresh faecal samples from Atg5-Wt, Atg5ΔMye, and Atg5ΔMyeIL-12KO mice were collected fresh in sterile tubes and flash-frozen.
Microbial communities were determined by sequencing of the 16S

4.5. Statistical analysis
Statistical analysis was performed as described in figure legends, and
graphs generated display mean (± standard deviation [SD]) and were
obtained using Prism software. Microbiome data were sequenced
and processed by Illumina’s service laboratory using their in-house
analysis pipeline. Cluster analysis was performed using heatmap3152
package in R. T testing was used to measure specific microbiome
species abundance between conditions. Adjusted p-value >0.05 was
used as significant threshold. Principal coordinate analysis was conducted in R. Confocal images statistical analysis and additional software Pearson’s correlation coefficient were acquired from BMM
images using Huygens’s Deconvolution Scientific Volume Image
Software [UNM Fluorescence Microscopy and Cell Imaging shared
resource]. Quantification figures were also made using Prism, and
confocal image figures were constructed using Adobe Illustrator [version CC 2019]. All other data were analysed using one-way analysis
of variance [ANOVA] or two-tailed unpaired Student’s t test [Prism].
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